Changes

Jump to: navigation, search

Adalimumab

260 bytes added, 15:17, 4 February 2019
no edit summary
|2 hours
|-
|R-Biopharm AG<ref name=”[30]”>GN3043 RIDA®QUICK ADM Monitoring (2018). Leaflet ''GN3043 RIDA®QUICK ADM Monitoring''. R-Biopharm AG.</ref>
|GN3043
|RIDA®QUICK ADM Monitoring
|15 min.
|-
|BühlmannBÜHLMANN<ref name=”[31]”>LF-TLAD25 Quantum Blue® Adalimumab (2018). Leaflet ''LF-TLAD25 Quantum Blue® Adalimumab''. BÜHLMANN.</ref>
|LF-TLAD25
|Quantum Blue® Adalimumab
== Numbers ==
Rheumatoid arthritis affects around 1% of the world population per year.<ref name=”[3032]”>Marita Cross, M. et al. (2014). The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 study. ''Annals of Rheumatic diseases, 73'', 1316-1322. [https://doi.org/10.1136/annrheumdis-2013-204627 ''doi:10.1136/annrheumdis-2013-204627'']</ref> Global estimates in 2010 reported a prevalence rate of 0.35% for women and 0.13% for men. The prevalence of RA is higher in more developed countries.<ref name=”[3133]”>Fazal, S.A. et al. (2018). A Clinical Update and Global Economic Burden of Rheumatoid Arthritis. ''Endocrine, Metabolic &amp; Immune disorders - Drug Targets, 18''(2), 98-109. [https://doi.org/10.2174/1871530317666171114122417 ''doi:10.2174/1871530317666171114122417'']</ref> A study in the US reported an overall lifetime risk for RA of 3.6% for women and 1.7% for men. This corresponds to around 1 in 28 women and 1 in 59 men that will develop RA in their lifetime.<ref name=”[3234]”>Crowson, C.S. et al. (2011). The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. ''Arthritis and Rheumatism, 63''(3), 633-639. [https://doi.org/10.1002/art.30155 ''doi:10.1002/art.30155'']</ref>
Globally in 2010, RA represented 0.49% of years lived with disability (YLD) and 0.19% of disability-adjusted-years (DALY). Across 31 nations in the period of 2009–2011, a total of 219,189 patients died, in whom RA was registered as the underlying cause of death. The YLDs for RA were 55/100000 population and the total DALYs were around 4.8 million.<ref name=”[3133]”>Fazal, S.A. et al. (2018). A Clinical Update and Global Economic Burden of Rheumatoid Arthritis. ''Endocrine, Metabolic &amp; Immune disorders - Drug Targets, 18''(2), 98-109. [https://doi.org/10.2174/1871530317666171114122417 ''doi:10.2174/1871530317666171114122417'']</ref>
The US reported having approximately $128 billion of direct and $47.0 billion of indirect costs billable to arthritis and related rheumatic conditions. In the UK, this number came down to £560 million a year in health care costs.<ref name=”[3133]”>Fazal, S.A. et al. (2018). A Clinical Update and Global Economic Burden of Rheumatoid Arthritis. ''Endocrine, Metabolic &amp; Immune disorders - Drug Targets, 18''(2), 98-109. [https://doi.org/10.2174/1871530317666171114122417 ''doi:10.2174/1871530317666171114122417'']</ref>In 2017, adalimumab (Humira) was at the top of pharmaceutical products by sales worldwide. The drug generated more than 18.4 billion US dollars. Almost twice as much as Rituxan, who took second place with 9.2 billion dollars generated.<ref name=”[3335]”>Statista (2018). Top 15 pharmaceutical products by sales worldwide in 2017. Accessed on 7 November 2018, at [https://www.statista.com/statistics/258022/top-10-pharmaceutical-products-by-global-sales-2011/ ''https://www.statista.com/statistics/258022/top-10-pharmaceutical-products-by-global-sales-2011/''].</ref> In 2015, Humira costs around $2669 per month in the US and $1362 in the UK.<ref name=”[3436]”>Statista (2018). Average prices of Humira in selected countries in 2015. Accessed on 7 November 2018, at [https://www.statista.com/statistics/312014/average-price-of-humira-by-country/ ''https://www.statista.com/statistics/312014/average-price-of-humira-by-country/''].</ref>
== References ==
<references />

Navigation menu